Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,000 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potential candidates for liver resection in liver-confined advanced HCC: a Chinese multicenter observational study.
Bai T, Wang E, Zhao S, Han D, Zhao Y, Chen H, Zhu J, Han T, Bai Y, Lou Y, Zhang Y, Yang M, Zuo L, Fan J, Chen X, Jia J, Wu W, Ren W, Zhu Y, Ma S, Xu F, Tang Y, Du X, Zhao J, Li J, Qi X, Han Y, Chen D, Liu L. Bai T, et al. Among authors: wang e. Front Oncol. 2023 Jun 26;13:1170923. doi: 10.3389/fonc.2023.1170923. eCollection 2023. Front Oncol. 2023. PMID: 37434986 Free PMC article.
Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study.
Zhu Y, Wang E, Zhao S, Han D, Zhao Y, Chen H, Zhu J, Han T, Bai Y, Lou Y, Zhang Y, Yang M, Zuo L, Fan J, Chen X, Jia J, Wu W, Ren W, Bai T, Ma S, Xu F, Tang Y, Han Y, Zhao J, Qi X, Li J, Du X, Chen D, Liu L. Zhu Y, et al. Among authors: wang e. Front Oncol. 2023 Jan 27;12:983554. doi: 10.3389/fonc.2022.983554. eCollection 2022. Front Oncol. 2023. PMID: 36776366 Free PMC article.
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Wang W, Bai W, Wang E, Zhao Y, Liu L, Yang M, Cai H, Xia D, Zhang L, Niu J, Yin Z, Zhang Z, Fan D, Xia J, Han G. Wang W, et al. Among authors: wang e. Int J Cancer. 2017 Jan 15;140(2):390-399. doi: 10.1002/ijc.30451. Epub 2016 Oct 17. Int J Cancer. 2017. PMID: 27681592 Free article.
Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study.
Wang Z, Wang E, Bai W, Xia D, Ding R, Li J, Wang Q, Liu L, Sun J, Mu W, Zhao H, Pan X, Shao G, Zhu X, Yin G, Shi H, Wu J, Lin Z, Yang S, Liu J, Wang W, Zhu X, Lv Y, Li J, Chen H, Wang W, Li K, Yuan X, Yu T, Yuan J, Li X, Niu J, Yin Z, Xia J, Fan D, Han G. Wang Z, et al. Among authors: wang w, wang e, wang q. Liver Cancer. 2020 Jun;9(3):308-325. doi: 10.1159/000505692. Epub 2020 Feb 19. Liver Cancer. 2020. PMID: 32647633 Free PMC article.
8,000 results